Novavax, Inc. Price & Performance (NVAX)

A new study from the University of Utah shows Novavax’s COVID-19 vaccine results in significantly fewer and milder side effects than Pfizer-BioNTech’s mRNA shot. Healthcare workers reported 39% fewer systemic symptoms and 67% less productivity loss, strengthening Novavax’s position as a tolerable alternative in the vaccine market.12

Novavax’s COVID-19 vaccine is still under FDA review for full approval, with analysts and investors maintaining a positive outlook. Recent data showing enhanced neutralizing antibody response and lower reactogenicity have driven optimism, while the company’s stock sentiment ranks above most industry peers.34

Despite recent market fluctuations, analysts see major upside potential for Novavax shares, with price targets reaching as high as $25.00. The company’s strong clinical results and outperforming sentiment metrics have contributed to an “Outperform” consensus from brokerage firms, even as valuation models suggest some downside risk.56